We serve Chemical Name:erythrosin B CAS:16423-68-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:erythrosin B
CAS.NO:16423-68-0
Synonyms:1427red;Erythrosin B,high purity,biological stain;Erythrosin;Tetraiodofluorescein sodium salt;Erythrosine Sodium (close form);Disodium 2-(2,4,5,7-tetraiodo-6-oxido-3-oxo-3H-xanthen-9-yl)benzoate;Benzoic acid, 2-(6-hydroxy-2,4,5,7-tetraiodo-3-oxo-3H-xanthen-9-yl)-, sodium salt (1:2);2′,4′,5′,7′-Tetraiodofluorescein disodium salt;Erythrosin extra bluish;IODOEOSIN;FD & C Red 3;Spiro[isobenzofuran-1(3H),9′-[9H]xanthen]-3-one, 3′,6′-dihydroxy-2′,4′,5′,7′-tetraiodo-, sodium salt (1:2);EINECS 240-474-8;3′,6′-Dihydroxy-2′,4′,5′,7′-tetraiodospiro[isobenzofuran-1(3H),9′-[9H]xanthen]-3-one Disodium Salt;FDC red no. 3;Disodium 2′,4′,5′,7′-tetraiodo-3-oxo-3H-spiro[2-benzofuran-1,9′-xanthene]-3′,6′-diolate;Sodium 2′,4′,5′,7′-tetraiodo-3-oxo-3H-spiro[isobenzofuran-1,9′-xanthene]-3′,6′-bis(olate);1671red;Food Red No. 3;c.i.773;Japan Red 3;EOSIN J;FD and C Red No. 3;Synerid;MFCD00144257;fdcred3;CRED3;ebs;Ceplac;Erythrosin B,certified;lb-rot1;Erythrosin B;Acid Red 51
Molecular Formula:C20H6I4Na2O5
Molecular Weight:879.856
HS Code:32129000
Physical and Chemical Properties:
Melting point:>300ºC (Decomposes)
Boiling point:693.2ºC at 760 mmHg
Density:0.98
Index of Refraction:
PSA:81.65000
Exact Mass:879.618896
LogP:6.96060
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like 1427red chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Acid Red 51 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,FDC red no. 3 Use and application,FD & technical grade,usp/ep/jp grade.
Related News: Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity. erythrosin B manufacturer We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries. erythrosin B supplier Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity. erythrosin B vendor We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries. erythrosin B factory But even though weight-loss success depends on adopting a challenging” change in post-operation diet and lifestyle, the process can certainly “help people to lose weight and get comorbid [other negative health] conditions under better control,” Sandon said.
So it’s important, she said, to help eligible patients better “understand the treatment options and potential for success,” by sharing surgery success stories and highlighting the benefits of reducing high-risk health issues such as blood pressure and diabetes.
An experimental Alzheimer’s vaccine appears to safely clear abnormal tau protein from the brain, but it’s not yet clear whether the shot will be able to save brain function.
In a Phase 2 clinical trial, the vaccine produced high levels of antibodies to target and attack free-floating tau proteins before they can form “tau tangles” that clog neurons and damage brain function. Tau tangles, along with plaques formed by the protein amyloid-beta, serve as one of the main hallmarks of Alzheimer’s.
“While amyloid influences speed of Alzheimer’s progression, there is strong evidence that tau pathology relates to the underlying cause of the disease,” said lead researcher Dr. Petr Novak, a senior clinical research scientist at AXON Neuroscience, the Slovakian pharmaceutical company developing the vaccine. “Brain atrophy and cognitive loss closely echo the deposition of pathological tau protein, as evidenced by recent tau PET studies.
So it’s important, she said, to help eligible patients better “understand the treatment options and potential for success,” by sharing surgery success stories and highlighting the benefits of reducing high-risk health issues such as blood pressure and diabetes.
An experimental Alzheimer’s vaccine appears to safely clear abnormal tau protein from the brain, but it’s not yet clear whether the shot will be able to save brain function.
In a Phase 2 clinical trial, the vaccine produced high levels of antibodies to target and attack free-floating tau proteins before they can form “tau tangles” that clog neurons and damage brain function. Tau tangles, along with plaques formed by the protein amyloid-beta, serve as one of the main hallmarks of Alzheimer’s.
“While amyloid influences speed of Alzheimer’s progression, there is strong evidence that tau pathology relates to the underlying cause of the disease,” said lead researcher Dr. Petr Novak, a senior clinical research scientist at AXON Neuroscience, the Slovakian pharmaceutical company developing the vaccine. “Brain atrophy and cognitive loss closely echo the deposition of pathological tau protein, as evidenced by recent tau PET studies.
